CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Metastatic Triple-Negative Breast Carcinoma;   Prognostic Stage IV Breast Cancer AJCC v8 Intervention:   Biological: Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials